Clinical trials: SARS-COV2
SARS-CoV-2
DUR-928 in Subjects With SARS-CoV-2 With Acute Lung, Liver or Kidney Injury
Evaluate safety and efficacy of DUR-928 in treatment of acute organ failure in subjects infected with SARS-CoV-2
- Trial name
- NCT04447404
- Testing
- DUR-928
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Durect
COVID-19
Phase 3 Adolescent Study for SARS-CoV-2 rS Variant Vaccines
This study is a large-scale investigation (Phase 3) into a new booster shot designed specifically for teenagers. The booster targets a particular variant of COVID-19, Omicron XBB.1.5.
- Trial name
- COVID-19 (NCT05973006)
- Testing
- NVX-CoV2601 co-formulated Omicron XBB.1.5 SARS-CoV-2 rS vaccine, Prototype/XBB.1.5 Bivalent Vaccine (5 µg)
- Where
- 20 sites in United States
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Novavax
COVID-19
Study of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalized Patients
The primary objective of this study is to evaluate the time to confirmed clinical recovery in participants hospitalized with COVID-19.
- Trial name
- COMMUNITY (NCT04590586)
- Testing
- Standard of care, Apremilast, Lanadelumab
- Where
- 59 sites in United States, Argentina and 6 more
- Volunteers
- 515 people
- Sponsor
- Amgen
COVID-19 Pneumonia
Tofacitinib for Treatment of Moderate COVID-19
The purpose of this randomized, double blinded, placebo controlled study is to assess the efficacy and safety of tofacitinib in hospitalized adult (18-99 years old) patients with SARS-CoV-2 and pneumonia who require supplemental…
- Trial name
- I-TOMIC (NCT04415151)
- Testing
- Tofacitinib 10 mg
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Yale University
Covid19, SARS-CoV-2
A Phase 2b/3, Randomized, Observer-Blinded, Placebo-Controlled, Multicenter Clinical Study Evaluating the Efficacy and Safety of Investigational SARS-CoV-2 mRNA Vaccine CVnCoV in Adults 18 Years of Age and Older
The primary objective of the randomized observer-blinded phase 2b/3 part of this trial is to demonstrate the efficacy of a 2-dose schedule of CVnCoV in the prevention of first episodes of virologically-confirmed cases of COVID-19…
- Trial name
- NCT04652102
- Testing
- CVnCoV, Authorized/licensed vaccines for preventing COVID-19 (AV) as standard of care through their national vaccination program
- Where
- 46 sites in Argentina, Belgium and 8 more
- Volunteers
- 39,680 people, healthy volunteers welcome
- Sponsor
- CureVac
SARS-CoV-2 Infection, COVID-19
A Study to Learn About New COVID-19 RNA Vaccine Candidates in COVID-19 Vaccine-Experienced Healthy Individuals
The purpose of this clinical trial is to learn about the safety, tolerability and immunogenicity of BNT162b RNA-based SARS-CoV-2 vaccine candidates in adults to prevent COVID-19.
- Trial name
- NCT05472038
- Testing
- BNT162b5 Bivalent (WT/OMI BA.2), BNT162b2 Bivalent (WT/OMI BA.1), BNT162b2 Bivalent (WT/OMI BA.4/BA.5)
- Where
- 31 sites in United States
- Volunteers
- 1,453 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
SARS (Severe Acute Respiratory Syndrome), Coronavirus
Nitric Oxide Gas Inhalation in Severe Acute Respiratory Syndrome in COVID-19
Severe acute respiratory syndrome (SARS-CoV2) due to novel Coronavirus (2019-nCoV) related infection (COVID-19) is characterized by severe ventilation perfusion mismatch leading to refractory hypoxemia.
- Trial name
- NOSARSCOVID (NCT04306393)
- Testing
- Nitric Oxide Gas
- Where
- 5 sites in United States, Sweden
- Volunteers
- 200 people
- Sponsor
- Massachusetts General Hospital
Covid19
Balance Function in Patients Post Corona Virus Disease 2019 (COVID-19)
The purpose of this study is to describe balance deficits in patients post COVID-19. The information the investigators learn may help influence balance training exercises for patients post-COVID-19.
- Trial name
- NCT04914364
- Testing
- Balance assessments
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Duke University
Immunization Against COVID-19
Efficacy and Safety of Ergoferon for COVID-19 Prevention During Vaccination Against SARS-CoV-2
The multicenter, double-blind, placebo-controlled, parallel-group, randomized clinical trial. The objective of this study is to evaluate the efficacy and safety of Ergoferon as a non-specific preventive medicine for COVID-19 in…
- Trial name
- NCT05069649
- Testing
- Ergoferon
- Where
- 33 sites in Russia
- Volunteers
- 1,057 people
- Sponsor
- Materia Medica Holding
SARS-CoV-2
Efficacy and Safety of Emapalumab and Anakinra in Reducing Hyperinflammation and Respiratory Distress in Patients With COVID-19 Infection.
Hyper-inflammation, caused by a cytokine storm resulting from an exaggerated response of the immune system in the presence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is considered to represent one of the…
- Trial name
- NCT04324021
- Testing
- Emapalumab, Anakinra
- Where
- 12 sites in United States, Italy
- Volunteers
- 16 people
- Sponsor
- Swedish Orphan Biovitrum
Infections, Respiratory, Virus Diseases
A Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-19 in Healthy and Immunocompromised Adults
Originally, the study was planned to include two parts, i.e., Part A and Part B, however Part B was cancelled due to changes in the overall clinical development plan.
- Conditions
- Infections, Respiratory, Virus Diseases, Infection Viral, Vaccine Adverse Reaction
- Trial name
- NCT04380701
- Testing
- BNT162a1, BNT162b1, BNT162b2
- Where
- 5 sites in Germany
- Volunteers
- 512 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
COVID-19
Q-POC SARS-CoV-2 Assay COVID-19 Clinical Evaluation
Q-POC SARS-CoV-2 moderate complexity PCR test performance evaluation
- Trial name
- NCT05614011
- Testing
- RT-PCR Test, Real-time PCR Test
- Where
- 3 sites in United States
- Volunteers
- 877 people
- Sponsor
- QuantuMDx Group Ltd
Covid19, Coronavirus Infection
COVFIS-HOME: COVID-19 Pilot Study of Fisetin to Alleviate Dysfunction and Decrease Complications
The purpose of this study is to test whether Fisetin, a senolytic drug can assist in the reduction of complications in patients with COVID-19 infection.
- Trial name
- COVFIS-HOME (NCT04771611)
- Testing
- Fisetin
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- James L. Kirkland, MD, PhD
COVID-19, Venous Thromboses
Intermediate or Prophylactic-Dose Anticoagulation for Venous or Arterial Thromboembolism in Severe COVID-19
This study is being conducted to assess the effectiveness of intermediate versus prophylactic doses of anticoagulation (blood thinners) in patients critically ill with COVID-19 in the intensive care units (ICUs) throughout the…
- Conditions
- COVID-19, Venous Thromboses, Arterial Thrombosis
- Trial name
- IMPROVE (NCT04367831)
- Testing
- Enoxaparin Prophylactic Dose, Heparin Infusion, Heparin SC
- Where
- United States
- Volunteers
- 94 people
- Sponsor
- Columbia University
COVID-19
Losmapimod Safety and Efficacy in COVID-19
The therapeutic hypothesis for the use of losmapimod in COVID-19 disease is that increased mortality and severe disease is caused by p38 mitogen-activated protein kinase (MAPK)-mediated exaggerated acute inflammatory response…
- Trial name
- LOSVID (NCT04511819)
- Testing
- Losmapimod oral tablet
- Where
- 16 sites in United States, Brazil and 2 more
- Volunteers
- 52 people
- Sponsor
- Fulcrum Therapeutics
Covid19
Intravenous Infusion of CAP-1002 in Patients With COVID-19
This is a randomized, double-blind, placebo-controlled, Pilot, Phase 2 Exploratory study that will enroll subjects with a clinical diagnosis of COVID-19 confirmed by laboratory testing and who are in severe or critical condition…
- Trial name
- INSPIRE (NCT04623671)
- Testing
- CAP-1002
- Where
- 4 sites in United States
- Volunteers
- 55 people
- Sponsor
- Capricor Inc.
Covid19, SARS-CoV2 Infection
SARS-CoV-2 Immune Responses After COVID-19 Therapy and Subsequent Vaccine
The purpose of this study is to evaluate the safety and efficacy of mRNA COVID-19 vaccines in: People with prior COVID-19 (SARS-CoV-2 infection) who were in the ACTIV-2/A5401 study.
- Trial name
- NCT04952402
- Testing
- Study-provided Moderna mRNA-1273 COVID-19 vaccine, Community-provided Moderna mRNA-1273 COVID-19 Vaccine, Community-Provided Pfizer-BioNTech BNT162b2 COVID-19 Vaccine
- Where
- 6 sites in United States
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
COVID-19, SARS-CoV 2
Antiseptic Mouthwash / Pre-Procedural Rinse on SARS-CoV-2 Load (COVID-19)
In this pilot trial, 150 confirmed COVID-19 individuals will be randomly assigned to 1 of 5 groups: distilled water, CloSYS Ultra Sensitive Rinse (Rowpar Pharmaceutical Inc., USA), Oral-B Mouth Sore (Oral-B, USA), Crest…
- Conditions
- COVID-19, SARS-CoV 2, Severe Acute Respiratory Syndrome Coronavirus 2, Virus Disease
- Trial name
- AMPoL (NCT04409873)
- Testing
- Oral-B Mouth Sore mouthwash, Crest Pro-Health Multi-Protection mouthwash, CloSYS Ultra Sensitive Rinse mouthwash
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- University of California, San Francisco
COVID-19
Safety and Efficacy of Melatonin in Outpatients Infected With COVID-19
This study is a pilot randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of melatonin in adult outpatients suspected to be afflicted with COVID-19.
- Trial name
- COVID-19 (NCT04474483)
- Testing
- Melatonin
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- State University of New York at Buffalo
Kidney Transplant Recipients, Liver Transplant Recipients
COVID Protection After Transplant-Immunosuppression Reduction
This study will enroll individuals who have: Completed primary series of mRNA COVID-19 vaccine, and An antibody response ≤ 2500 U/mL measured at least 30 days after the last dose of vaccine.
- Trial name
- CPAT-ISR (NCT05077254)
- Testing
- Pfizer-BioNTech COVID-19 Vaccine 2023-2024, Moderna COVID-19 Vaccine 2023-2024, SOC IS Regimen
- Where
- 15 sites in United States
- Volunteers
- 48 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)